
-
Trans rights supporters rally outside in London, Edinburgh after landmark ruling
-
PSG beat Le Havre to stay on course for unbeaten Ligue 1 season
-
Man City close in on Champions League with Everton late show
-
14-year-old Vaibhav Suryavanshi becomes youngest IPL player
-
Barca make stunning comeback to beat Celta Vigo in Liga thriller
-
Zverev sets up birthday bash with Shelton in Munich
-
Man City boost top five bid, Southampton snatch late leveller
-
US Supreme Court intervenes to pause Trump deportations
-
Alcaraz and Rune race into Barcelona final
-
US, Iran to hold more nuclear talks after latest round
-
Man City close in on Champions League thanks to Everton late show
-
Bayern close in on Bundesliga title with Heidenheim thumping
-
Tunisia opposition figures get jail terms in mass trial
-
Putin announces 'Easter truce' in Ukraine
-
McLaren duo in ominous show of force in Saudi final practice
-
Afghan PM condemns Pakistan's 'unilateral' deportations
-
Iran says to hold more nuclear talks with US after latest round
-
Comeback queen Liu leads US to World Team Trophy win
-
Buttler fires Gujarat to top of IPL table in intense heat
-
Unimpressive France stay on course for Grand Slam showdown
-
Shelton fights past Cerundolo to reach Munich ATP final
-
Vance and Francis: divergent values but shared ideas
-
Iran, US conclude second round of high-stakes nuclear talks in Rome
-
Dumornay gives Lyon first leg lead over Arsenal in women's Champions League semis
-
Trans rights supporters rally outside UK parliament after landmark ruling
-
Rune destroys Khachanov to reach Barcelona Open final
-
From Messi to Trump, AI action figures are the rage
-
Vance discusses migration during Vatican meeting with pope's right-hand man
-
Afghan FM tells Pakistan's top diplomat deportations are 'disappointment'
-
British cycling icon Hoy and wife provide solace for each other's ills
-
Money, power, violence in high-stakes Philippine elections
-
Iran, US hold second round of high-stakes nuclear talks in Rome
-
Japanese warships dock at Cambodia's Chinese-renovated naval base
-
US Supreme Court pauses deportation of Venezuelans from Texas
-
Pakistan foreign minister arrives in Kabul as Afghan deportations rise
-
Heat and Grizzlies take final spots in the NBA playoffs
-
Iran, US to hold second round of high-stakes nuclear talks in Rome
-
Humanoid robots stride into the future with world's first half-marathon
-
Migrant's expulsion puts Washington Salvadorans on edge
-
Plan for expanded Muslim community triggers hope, fear in Texas
-
Pakistan foreign minister due in Kabul as deportations rise
-
White House touts Covid-19 'lab leak' theory on revamped site
-
Dodgers star Ohtani skips trip to Texas to await birth of first child
-
How Motorcycling Builds Life-Long Friendships
-
SFWJ / Medcana Announces Strategic Expansion Into Australia With Acquisition of Cannabis Import and Distribution Licenses
-
US senator says El Salvador staged 'margarita' photo op
-
Ford 'adjusts' some exports to China due to tariffs
-
Thomas maintains two-shot lead at RBC Heritage
-
US to withdraw some 1,000 troops from Syria
-
Four killed after spring storms wreak havoc in the Alps

Japan biochemist who discovered statins, Akira Endo, dies
Japanese biochemist Akira Endo, who discovered cholesterol-lowering statins, has died aged 90, his former student and colleague said on Tuesday.
Statins, which can prevent heart attacks or strokes, are among the most commonly prescribed drugs worldwide.
Keiji Hasumi, a professor who was a long-time associate of Endo, said the scientist had died on June 5.
"His work was truly great. Statins didn't exist before Endo," Hasumi told AFP. "It has the same value and impact as the discovery of penicillin."
Johns Hopkins Medicine says more than 200 million people take statins. Studies say the global market for them was worth $15 billion in 2023 and is expected to grow.
Endo experimented on thousands of microbes to reach his 1973 discovery of mevastatin -- an agent derived from penicillin that reduces so-called "bad" cholesterol in the blood.
The researcher "was a tough, strict person. He was insightful and perceptive," and "able to see the hidden essence of things", Hasumi said.
Endo was born in 1933 to a farming family in rural northern Japan.
His ambitions began early thanks to his grandfather, who was interested in medicine and became a "great home teacher", Endo said in a 2008 autobiographical essay.
As a student, Endo became interested in antibiotics like penicillin, "deeply impressed" by how many lives they had saved, his essay in the journal Nature Medicine said.
Endo carried out research in New York in the late 1960s, when coronary heart disease was the main cause of US deaths.
"I often saw ambulances coming to take elderly people who had suffered a heart attack to hospital", which "made me realise the importance of developing a cholesterol-lowering drug", he said.
Endo worked at the Tokyo University of Agriculture and Technology, which issued a statement expressing condolences over his death, and at Japanese drugmaker Sankyo, now a part of Daiichi-Sankyo.
He spent two years testing 6,000 strains of microbe in the search for a new drug that could help achieve his goal before finally finding mevastatin.
Conflicting reports on the benefits and potential harms of statins in recent years have prompted some people prescribed the drugs to stop taking them.
"Are statins safe? For most people, the answer is a resounding yes, according to a 2014 Johns Hopkins meta-analysis of 20 years worth of published research," the US university says.
Endo was a strong candidate for a Nobel Prize, but never won. In a report on his death, Japanese broadcaster NHK noted Endo had received other accolades, including being honoured as a Person of Cultural Merit by the government in 2011.
His discovery "was the result of many twists and turns", Hasumi said.
"He reached his goal by overcoming so many challenges, without which medicines cannot be created, I think I remember him saying."
Y.Kobayashi--AMWN